Alnylam Pharmaceuticals (ALNY) reported quarterly earnings results on Monday, May-2-2016. The company reported $-1.21 earnings per share for the quarter, missing the analyst consensus estimate by $-0.12. Analysts had a consensus of $-1.09. The company posted revenue of $7.35 million in the period, compared to analysts expectations of $7.74 million. The company’s revenue was down -60.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.62 EPS.
Many Wall Street Analysts have commented on Alnylam Pharmaceuticals. Chardan Capital Markets Initiated Alnylam Pharmaceuticals on Apr 5, 2016 to “Buy”, Price Target of the shares are set at $93.Alnylam Pharmaceuticals was Upgraded by JP Morgan to ” Overweight” on Mar 11, 2016. Shares were Reiterated by Leerink Partners on Feb 16, 2016 to “Outperform” and Lowered the Price Target to $ 120 from a previous price target of $152 .
Alnylam Pharmaceuticals closed down -1.74 points or -2.47% at $68.63 with 4,46,854 shares getting traded on Wednesday. Post opening the session at $70.43, the shares hit an intraday low of $68.37 and an intraday high of $70.765 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Apr 21, 2016, John Maraganore (Chief Executive Officer) sold 30,151 shares at $67.87 per share price. According to the SEC, on Mar 10, 2016, Michael W Bonney (director) purchased 2,000 shares at $58.36 per share price. On Dec 4, 2015, Philip A Sharp (director) sold 30,000 shares at $109.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Companys pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease with a pipeline of RNAi therapeutics toward genetically validated liver-expressed disease in cardiovascular and metabolic diseases and hepatic infectious disease with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02) Revusiran (ALN-TTRsc) ALN-AT3 ALN-CC5 ALN-AS1 ALN-AAT ALN-GO1 ALN-TMP ALN-PCS ALN-PCSsc ALN-AC3 ALN-ANG ANGPTL3 ALN-HBV ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.